Pharmacovigilance – News and Features

Research led by Carnegie Mellon scientists finds many genes are inactivated in cancer cells.

Nanolymf is dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs.

Company has initiated separate Phase 2 clinical trials of XP19986 in patients with gastroesophageal reflux disease and in spinal cord injury patients with spasticity.

The study was aimed at investigating safety/tolerability, pharmacokinetics, and pharmacodynamics during prolonged dosing with EVT 302 as compared to placebo.

Compound 642444 and compound 685698 advance in clinical development for the treatment of asthma.

Discovery is a step closer to a universal stem cell line for human therapeutics and creation of a global stem cell bank.

Stealth Biotech announced today its plans to target specific microRNA:mRNA interactions for development of novel oligonucleotide-based therapeutics.

Evotec AG and Renovis, Inc. today announced that they have entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases, in a stock-for-stock transaction valued at approximately US$ 151.8 million.

Southern Illinois University’s researchers presented the results of a study using nab-paclitaxel and bevacizumab to treat lymphatic and pulmonary metastases in female SCID mice.

The Company finalized its Phase IIb Oxycyte clinical trial and plans to initiate three pre-clinical animal studies in sickle cell disease, spinal cord injury and stroke in the first half of 2008.